(Q57578399)
Statements
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an (English)
0 references
April 2008
0 references
26
0 references
10
0 references
1642-1649
0 references